戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nts undergoing femoro-popliteal percutaneous transluminal angioplasty.
2 strategies to treat atherosclerosis, such as transluminal angioplasty and stent implantation, often c
3 in the medical group versus the percutaneous transluminal angioplasty and stenting (PTAS) group (p=0.
4 increasingly being treated with percutaneous transluminal angioplasty and stenting (PTAS) to prevent
5                RECENT FINDINGS: Percutaneous transluminal angioplasty and stenting is a treatment opt
6  are not randomized and receive percutaneous transluminal angioplasty and stenting or femoropopliteal
7 ither femoropopliteal bypass or percutaneous transluminal angioplasty and stenting; patients with TAS
8 temporary studies of the use of percutaneous transluminal angioplasty as primary treatment for patien
9                    Two balloon (percutaneous transluminal angioplasty) catheters were used.
10 s (2005-2015) on the effects of percutaneous transluminal angioplasty for the treatment of infrapopli
11        Contemporary outcomes of percutaneous transluminal angioplasty for the treatment of infrapopli
12           At many institutions, percutaneous transluminal angioplasty has become the treatment of cho
13                      Peripheral percutaneous transluminal angioplasty is fraught with a substantial r
14  peripheral artery disease with percutaneous transluminal angioplasty is limited by the occurrence of
15 pectoris when bypass surgery or percutaneous transluminal angioplasty is not indicated.
16 sions <80 mm underwent percutaneous coronary transluminal angioplasty, laser ablation, and/or rotatio
17 lihood of technical success for percutaneous transluminal angioplasty of dialysis access venous steno
18 ion bias were observed for most percutaneous transluminal angioplasty outcomes.
19 th critical limb ischemia using percutaneous transluminal angioplasty (PTA) and bail-out bare metal s
20 and reintervention rates versus percutaneous transluminal angioplasty (PTA) and improve wound healing
21   The RCT compared the DES with percutaneous transluminal angioplasty (PTA) and provisional bare-meta
22 h a low-dose DCB or an uncoated percutaneous transluminal angioplasty (PTA) balloon.
23 accesses that underwent balloon percutaneous transluminal angioplasty (PTA) between January 2009 and
24 ng balloons versus conventional percutaneous transluminal angioplasty (PTA) for the reduction of rest
25  paclitaxel-coated balloon with percutaneous transluminal angioplasty (PTA) for the treatment of symp
26 esions that are not amenable to percutaneous transluminal angioplasty (PTA) or for recurrence after P
27 her (all P<.001) than those for percutaneous transluminal angioplasty (PTA), as were radiation exposu
28 omes compared with conventional percutaneous transluminal angioplasty (PTA), yet durability of the tr
29 d the patency rate of SFA after percutaneous transluminal angioplasty (PTA).
30 n renal function at the time of percutaneous transluminal angioplasty (PTA).
31 n=200) or standard angioplasty (percutaneous transluminal angioplasty [PTA]) (n=100).
32 ating vascular restenosis after percutaneous transluminal angioplasty remains a formidable challenge.
33 avian-carotid bypass and 5 with percutaneous transluminal angioplasty stenting of the subclavian).
34          In the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS), early recurren
35  results of the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS).
36 ventions after femoro-popliteal percutaneous transluminal angioplasty up to 1 year of follow-up.
37 fully undergone angiography and percutaneous transluminal angioplasty using CO2 as the sole contrast
38                                 Percutaneous transluminal angioplasty was then performed in 18 of the
39 erosclerotic disease undergoing percutaneous transluminal angioplasty were randomized to paclitaxel-c
40 teal peripheral artery disease, percutaneous transluminal angioplasty with a paclitaxel-coated balloo

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。